Literature DB >> 3153322

Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders.

H W Seyberth1, S J Königer, W Rascher, P G Kühl, H Schweer.   

Abstract

Renal and systemic prostanoid activity was assessed in various renal tubular disorders, using mass spectrometric determination of urinary excretion rates of primary prostaglandins (PGE2, PGF2 alpha, PGI2, and TXA2) and their systemically produced index metabolites. Only PGE2 levels (normal range: 2.0-16.4 ng/h per 1.73 m2) are elevated in Bartter syndrome (median: 43.4, range: 6.7-166.3), nephrogenic diabetes insipidus (46.2, 12.1-1290), Fanconi syndrome (96.6, 19.3-135.5), and in a complex tubular disorder in premature infants (40.7, 22.3-132.1), for which the term hyperprostaglandin E syndrome has been introduced. In this disorder with a Bartter-syndrome-like tubulopathy, the systemic features of the disease such as fever, diarrhoea and osteopenia with hypercalciuria were associated with increased systemic PGE2 activity. In most patients the urinary excretion rate of the systemic index metabolite of PGE2 (PGE-M) was markedly elevated (1028, 285-4709; normal range: 104-664 ng/h per 1.73 m2). Hypercalciuria per se was associated neither with increased renal nor with systemic PGE2 hyperactivity. Most problems in infants with hyperprostaglandin E syndrome could be controlled by long-term indomethacin treatment in contrast to the moderate and partial effect of this treatment in patients with Fanconi syndrome. Thus increased PGE2 synthesis plays a major role in the pathogenesis of hyperprostaglandin E syndrome, while in Fanconi syndrome PGE2 hyperactivity in the kidney is a secondary event and only aggravates the water and electrolyte wastage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3153322     DOI: 10.1007/bf00849259

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  19 in total

1.  Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin.

Authors:  R Verberckmoes; B van Damme B; J Clement; A Amery; P Michielsen
Journal:  Kidney Int       Date:  1976-03       Impact factor: 10.612

Review 2.  Prostaglandins and other arachidonic acid metabolites in the kidney.

Authors:  D Schlondorff; R Ardaillou
Journal:  Kidney Int       Date:  1986-01       Impact factor: 10.612

3.  The pathogenetic spectrum of Bartter's syndrome.

Authors:  J H Stein
Journal:  Kidney Int       Date:  1985-07       Impact factor: 10.612

4.  Mass spectrometric determination of urinary prostaglandins in preterm infants. The basis for an effective and safe therapeutic regimen for the pharmacological closure.

Authors:  H W Seyberth; H Müller; T Erlenmaier; R Mrongovius
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

5.  Idiopathic hypercalciuria associated with hyperreninemia and high urinary prostaglandin E.

Authors:  M Houser; B Zimmerman; M Davidman; C Smith; A Sinaiko; A Fish
Journal:  Kidney Int       Date:  1984-08       Impact factor: 10.612

6.  Prostaglandins are overproduced by the kidneys and mediate hyperreninemia in Bartter's syndrome.

Authors:  F C Bartter; J R Gill; J C Frolich; R E Bowden; J W Hollifield; N Radfar; H R Keiser; J A Oates; H Seyberth; A A Taylor
Journal:  Trans Assoc Am Physicians       Date:  1976

Review 7.  Role of prostaglandins in the pathogenesis of Bartter's syndrome.

Authors:  M P Fichman; N Telfer; P Zia; P Speckart; M Golub; R Rude
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

8.  Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome.

Authors:  H W Seyberth; W Rascher; H Schweer; P G Kühl; O Mehls; K Schärer
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

9.  Systemic prostaglandin I2 synthesis is normal in patients with Bartter's syndrome.

Authors:  M L Watson; J R Gill; R A Branch; J A Oates; A R Brash
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

10.  Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin.

Authors:  W Rascher; W Rosendahl; I A Henrichs; R Maier; H W Seyberth
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

View more
  23 in total

Review 1.  The pathophysiological and molecular basis of Bartter's and Gitelman's syndromes.

Authors:  S Bhandari
Journal:  Postgrad Med J       Date:  1999-07       Impact factor: 2.401

2.  Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndrome.

Authors:  R Vargas-Poussou; D Feldmann; M Vollmer; M Konrad; L Kelly; L P van den Heuvel; L Tebourbi; M Brandis; L Karolyi; S C Hebert; H H Lemmink; G Deschênes; F Hildebrandt; H W Seyberth; L M Guay-Woodford; N V Knoers; C Antignac
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

3.  Uncompensated polyuria in a mouse model of Bartter's syndrome.

Authors:  N Takahashi; D R Chernavvsky; R A Gomez; P Igarashi; H J Gitelman; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 4.  Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs.

Authors:  Noritaka Kawada; Toshiki Moriyama; Harumi Kitamura; Ryohei Yamamoto; Yoshiyuki Furumatsu; Isao Matsui; Yoshitsugu Takabatake; Yasuyuki Nagasawa; Enyu Imai; Christopher S Wilcox; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

Review 5.  Eicosanoids and tumor necrosis factor-alpha in the kidney.

Authors:  Nicholas R Ferreri; Shoujin Hao; Paulina L Pedraza; Bruno Escalante; Carlos P Vio
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-11-11       Impact factor: 3.072

6.  Gitelman's syndrome is genetically distinct from other forms of Bartter's syndrome.

Authors:  L Károlyi; A Ziegler; M Pollak; M Fischbach; K H Grzeschik; M C Koch; H W Seyberth
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

7.  Pre-pubertal growth in the hyperprostaglandin E syndrome.

Authors:  C Seidel; S Reinalter; H W Seyberth; K Schärer
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

Review 8.  Bartter syndrome complicated by immune complex nephropathy. Case report and literature review.

Authors:  Yahya Sardani; Kenan Qin; Mark Haas; Andrew J Aronson; Robert L Rosenfield
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

9.  Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT).

Authors:  R Lu; N Kanai; Y Bao; V L Schuster
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

Review 10.  Isoforms of renal Na-K-2Cl cotransporter NKCC2: expression and functional significance.

Authors:  Hayo Castrop; Jurgen Schnermann
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.